Online inquiry

IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ758MR)

This product GTTS-WQ758MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LOXL2 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002318.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4017
UniProt ID Q9Y4K0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ758MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6361MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ12900MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ15679MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA VB6-845
GTTS-WQ8617MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuM195
GTTS-WQ3186MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ11105MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MDX-060
GTTS-WQ1135MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ8494MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA hu1124
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW